🇺🇸 GH — Guardant Health, Inc.

Salud Compra fuerte
← Volver

Precio actual

175,00 USD

Máx. histórico

187,22

29 días

Caída desde máximo

-6,53%

Rango 52 semanas

74,55 – 191,05

Variación hoy

+2,50%

Cierre anterior

170,73

Rango de hoy

167,31 – 178,38

Volumen hoy

1.720.775

Peor caída histórica

-91,03%

12/02/2021 → 19/04/2024

Recuperado en 881 días

Volatilidad anualizada ⓘ

67,35%

Información
Nombre completo
Guardant Health, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Diagnostics & Research
Empleados
2.490
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
202,24 USD (puede no estar actualizado)
Primera cotización
04/10/2018
Precio actualizado
hace 12 horas
Sobre la empresa

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/03/2021 143,17 143,17 133,93 134,51 -5,92% 6,45% 616.100
23/03/2021 147,27 148,44 142,00 142,98 -2,65% 4,37% 658.400
22/03/2021 145,11 149,21 143,43 146,87 +0,91% 3,98% 626.300
19/03/2021 141,59 146,99 140,00 145,55 +2,85% 4,94% 986.000
18/03/2021 144,41 144,86 140,00 141,52 -2,98% 3,37% 790.800
17/03/2021 142,48 149,45 141,05 145,86 +0,25% 5,90% 723.900
16/03/2021 148,43 150,40 143,40 145,50 -0,01% 4,72% 698.700
15/03/2021 140,38 146,23 140,38 145,51 +1,78% 4,17% 709.400
12/03/2021 143,12 143,76 140,01 142,96 -1,37% 2,62% 557.700
11/03/2021 140,58 145,98 139,84 144,94 +6,03% 4,37% 1.032.000
10/03/2021 137,85 142,15 135,75 136,70 +0,31% 4,64% 889.200
09/03/2021 133,03 138,81 131,09 136,28 +6,61% 5,80% 1.185.600
08/03/2021 134,45 138,91 126,75 127,83 -5,50% 9,04% 1.570.000
05/03/2021 133,38 135,58 121,78 135,27 +1,59% 10,35% 2.163.900
04/03/2021 143,35 144,80 130,05 133,15 -7,34% 10,29% 1.739.100
03/03/2021 153,63 154,00 141,81 143,70 -7,07% 7,93% 1.327.400
02/03/2021 154,02 157,60 153,00 154,63 +1,64% 2,99% 1.123.200
01/03/2021 149,48 153,45 147,70 152,14 +3,37% 3,85% 671.100
26/02/2021 151,14 153,20 142,23 147,18 -1,52% 7,26% 1.406.100
25/02/2021 154,00 154,97 146,00 149,45 -7,88% 5,82% 2.986.300
24/02/2021 160,57 163,57 157,29 162,24 +1,31% 3,91% 665.000
23/02/2021 155,00 161,69 148,53 160,15 +0,13% 8,49% 1.364.000
22/02/2021 169,85 171,00 159,54 159,95 -6,16% 6,75% 779.900
19/02/2021 169,00 172,65 168,77 170,45 +1,86% 2,30% 545.700
18/02/2021 165,69 168,50 162,50 167,34 -0,75% 3,62% 580.600
17/02/2021 173,33 173,33 163,79 168,61 -2,67% 5,50% 578.700
16/02/2021 180,61 180,83 170,40 173,24 -3,27% 5,77% 1.017.600
12/02/2021 168,71 181,07 167,39 179,10 +6,41% 8,11% 1.294.600
11/02/2021 163,85 169,79 162,38 168,31 +3,88% 4,52% 1.257.900
10/02/2021 162,71 164,10 155,44 162,02 -0,81% 5,32% 691.100